ArticleFrontiers in medicine2025
The relationship between the intraocular position of dexamethasone intravitreal implant and post-injection intraocular pressure elevation.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sustained Intraocular Pressure Control After iStent InfiniteJournal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the relationship between the implantation position of dexamethasone intravitreal implant (DEX-I) and post-injection intraocular pressure (IOP) elevation. Methods: This retrospective study included 324 patients (332 eyes) who received at least one DEX-I injection between June 2020 and June 2024, with a follow-up period of at least 3 months. Patient demographics, diagnoses, and DEX-I implantation positions were recorded. The correlation between implantation position and post-injection IOP elevation was analyzed. IOP elevation was defined as an IOP greater than 25 mmHg and/or an increase of 10 mmHg from baseline. DEX-I implantation positions were defined as follows: P1: implant located in the vitreous near the ciliary body, anterior to the ora serrata (with or without ciliary body contact); P2: implant located in the vitreous from the ora serrata to the pre-equatorial region; P3: implant located in the post-equatorial vitreous. The equator was defined by the vortex veins. Results: During the follow-up period, 68 eyes (20.48%) experienced IOP elevation. Compared to P2 and P3, the P1 implantation position was significantly associated with a higher incidence of IOP elevation ( Conclusion: The P1 implantation is positively correlated with IOP elevation, particularly with early IOP elevation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.